ImpediMed (IPD.AX) Stock Price

ImpediMed Price

ASX·CLOSED
0.01AUD+0.0010 (+18.18 %)
Market closed

Over the last 19 years ImpediMed grew revenue by 13.9% annually, reaching 12.72 M AUD. For ImpediMed, the net margin of -182.6% is up versus -246.2% a few years ago. The consensus 12-month price target for ImpediMed is 0.05 AUD, about 750.0% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 50% above its 52-week low.

ImpediMed stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ImpediMed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ImpediMed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ImpediMed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ImpediMed Stock Price History
DateImpediMed Price
8/14/20260.01 AUD
8/13/20260.00 AUD
8/12/20260.00 AUD
8/11/20260.01 AUD
8/10/20260.01 AUD
8/7/20260.01 AUD
8/6/20260.00 AUD
8/5/20260.00 AUD
8/4/20260.00 AUD
8/3/20260.00 AUD
7/31/20260.00 AUD
7/30/20260.00 AUD
7/29/20260.00 AUD
7/28/20260.00 AUD
7/27/20260.00 AUD
7/24/20260.00 AUD
7/23/20260.00 AUD
7/22/20260.00 AUD
7/21/20260.00 AUD
7/20/20260.01 AUD
7/17/20260.01 AUD
7/16/20260.01 AUD
7/15/20260.01 AUD
7/14/20260.00 AUD
7/13/20260.01 AUD
7/10/20260.01 AUD
7/9/20260.01 AUD
7/8/20260.01 AUD
7/7/20260.01 AUD
7/6/20260.01 AUD
7/3/20260.01 AUD
7/2/20260.01 AUD
7/1/20260.01 AUD
6/30/20260.00 AUD
6/29/20260.00 AUD
6/26/20260.00 AUD
6/25/20260.00 AUD
6/24/20260.01 AUD
6/23/20260.01 AUD
6/22/20260.01 AUD
6/19/20260.01 AUD
6/18/20260.01 AUD
6/17/20260.01 AUD
6/16/20260.00 AUD
6/15/20260.01 AUD
6/12/20260.01 AUD
6/11/20260.01 AUD
6/10/20260.01 AUD
6/9/20260.01 AUD
6/5/20260.01 AUD
6/4/20260.01 AUD
6/3/20260.01 AUD
6/2/20260.01 AUD
6/1/20260.01 AUD
5/29/20260.01 AUD
5/28/20260.01 AUD
5/27/20260.01 AUD
5/26/20260.01 AUD
5/25/20260.01 AUD
5/22/20260.01 AUD
5/21/20260.01 AUD
5/20/20260.01 AUD
5/19/20260.01 AUD
5/18/20260.01 AUD
5/15/20260.01 AUD
5/14/20260.01 AUD
5/13/20260.01 AUD
5/12/20260.01 AUD
5/11/20260.01 AUD
5/8/20260.01 AUD
5/7/20260.01 AUD
5/6/20260.01 AUD
5/5/20260.01 AUD
5/4/20260.01 AUD
5/1/20260.01 AUD
4/30/20260.01 AUD
4/29/20260.01 AUD
4/28/20260.01 AUD
4/27/20260.01 AUD
4/24/20260.01 AUD
4/23/20260.01 AUD
4/22/20260.01 AUD
4/21/20260.01 AUD
4/20/20260.01 AUD
4/17/20260.01 AUD
4/16/20260.01 AUD
4/15/20260.01 AUD
4/14/20260.01 AUD
4/13/20260.01 AUD
4/10/20260.01 AUD
4/9/20260.01 AUD
4/8/20260.01 AUD
4/7/20260.01 AUD
4/2/20260.01 AUD
4/1/20260.01 AUD
3/31/20260.01 AUD
3/30/20260.01 AUD
3/27/20260.01 AUD
3/26/20260.01 AUD
3/25/20260.01 AUD
3/24/20260.01 AUD
3/23/20260.01 AUD
3/20/20260.01 AUD
3/19/20260.01 AUD
3/18/20260.01 AUD
3/17/20260.01 AUD
3/16/20260.01 AUD
3/13/20260.01 AUD
3/12/20260.01 AUD
3/11/20260.01 AUD
3/10/20260.01 AUD
3/9/20260.01 AUD
3/6/20260.01 AUD
3/5/20260.01 AUD
3/4/20260.01 AUD
3/3/20260.01 AUD
3/2/20260.01 AUD
2/27/20260.01 AUD
2/26/20260.01 AUD
2/25/20260.01 AUD
2/24/20260.01 AUD
2/23/20260.01 AUD
2/20/20260.01 AUD
2/19/20260.01 AUD
2/18/20260.01 AUD
2/17/20260.01 AUD
2/16/20260.01 AUD
2/13/20260.01 AUD
2/12/20260.01 AUD
2/11/20260.01 AUD
2/10/20260.01 AUD
2/9/20260.01 AUD
2/6/20260.01 AUD
2/5/20260.01 AUD
2/4/20260.01 AUD
2/3/20260.01 AUD
2/2/20260.01 AUD
1/30/20260.01 AUD
1/29/20260.01 AUD
1/28/20260.02 AUD
1/27/20260.02 AUD
1/23/20260.02 AUD
1/22/20260.02 AUD
1/21/20260.02 AUD
1/20/20260.02 AUD
1/19/20260.02 AUD
1/16/20260.02 AUD
1/15/20260.02 AUD
1/14/20260.02 AUD
1/13/20260.02 AUD
1/12/20260.02 AUD
1/9/20260.02 AUD
1/8/20260.02 AUD
1/7/20260.02 AUD
1/6/20260.02 AUD
1/5/20260.02 AUD
1/2/20260.02 AUD
12/31/20250.02 AUD
12/30/20250.02 AUD
12/29/20250.02 AUD
12/24/20250.02 AUD
12/23/20250.02 AUD
12/22/20250.02 AUD
12/19/20250.02 AUD
12/18/20250.02 AUD
12/17/20250.02 AUD
12/16/20250.02 AUD
12/15/20250.02 AUD
12/12/20250.02 AUD
12/11/20250.02 AUD
12/10/20250.02 AUD
12/9/20250.02 AUD
12/8/20250.02 AUD
12/5/20250.02 AUD
12/4/20250.02 AUD
12/3/20250.02 AUD
12/2/20250.02 AUD
12/1/20250.02 AUD
11/28/20250.02 AUD
11/27/20250.02 AUD
11/26/20250.02 AUD
11/25/20250.02 AUD
11/24/20250.02 AUD
11/21/20250.02 AUD
11/20/20250.02 AUD
11/19/20250.03 AUD
11/18/20250.02 AUD
11/17/20250.03 AUD
11/14/20250.03 AUD
11/13/20250.02 AUD
11/12/20250.02 AUD
11/11/20250.02 AUD
11/10/20250.02 AUD
11/7/20250.02 AUD
11/6/20250.02 AUD
11/5/20250.02 AUD
11/4/20250.02 AUD
11/3/20250.02 AUD
10/31/20250.02 AUD
10/30/20250.03 AUD
10/29/20250.03 AUD
10/28/20250.03 AUD
10/27/20250.03 AUD
10/24/20250.03 AUD
10/23/20250.03 AUD
10/22/20250.03 AUD
10/21/20250.03 AUD
10/20/20250.03 AUD
10/17/20250.03 AUD
10/16/20250.03 AUD
10/15/20250.03 AUD
10/14/20250.03 AUD
10/13/20250.03 AUD
10/10/20250.03 AUD
10/9/20250.03 AUD
10/8/20250.03 AUD
10/7/20250.03 AUD
10/6/20250.03 AUD
10/3/20250.03 AUD
10/2/20250.03 AUD
10/1/20250.02 AUD
9/30/20250.02 AUD
9/29/20250.02 AUD
9/26/20250.02 AUD
9/25/20250.02 AUD
9/24/20250.02 AUD
9/23/20250.02 AUD
9/22/20250.02 AUD
9/19/20250.02 AUD
9/18/20250.02 AUD
9/17/20250.02 AUD
9/16/20250.02 AUD
9/15/20250.03 AUD
9/12/20250.02 AUD
9/11/20250.03 AUD
9/10/20250.02 AUD
9/9/20250.03 AUD
9/8/20250.03 AUD
9/5/20250.03 AUD
9/4/20250.03 AUD
9/3/20250.03 AUD
9/2/20250.03 AUD
9/1/20250.03 AUD
8/29/20250.03 AUD
8/28/20250.03 AUD
8/27/20250.03 AUD
8/26/20250.03 AUD
8/25/20250.03 AUD
8/22/20250.03 AUD
8/21/20250.03 AUD
8/20/20250.03 AUD
8/19/20250.03 AUD
8/18/20250.03 AUD
Access this data via the Eulerpool API
Get Free API Key

ImpediMed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
8.41 M AUD
-21.23 M AUD
-20.71 M AUD
Jan 1, 2022
10.57 M AUD
-19.85 M AUD
-19.87 M AUD
Jan 1, 2023
11.34 M AUD
-21.26 M AUD
-20.52 M AUD
Jan 1, 2024
10.32 M AUD
-21.22 M AUD
-19.79 M AUD
Jan 1, 2025
12.72 M AUD
-23.01 M AUD
-23.24 M AUD
Jan 1, 2026 (e)
16.66 M AUD
-18.81 M AUD
-21.92 M AUD
Jan 1, 2027 (e)
23.31 M AUD
-14.51 M AUD
-16.31 M AUD
Jan 1, 2028 (e)
34.40 M AUD
-7.84 M AUD
-3.41 M AUD

ImpediMed Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 11:45 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
20132014201520162017201820192020202120222023202420252026e2027e2028e
2.003.004.005.006.003.004.005.008.0010.0011.0010.0012.0016.0023.0034.00
-33.3350.0033.3325.0020.00-50.0033.3325.0060.0025.0010.00-9.0920.0033.3343.7547.83
50.0066.6775.0080.0066.6766.6750.0080.0075.0080.0081.8290.0083.3383.3383.3383.33
1.002.003.004.004.002.002.004.006.008.009.009.0010.0013.3319.1728.33
-8.00-7.00-14.00-23.00-27.00-27.00-24.00-22.00-21.00-19.00-21.00-21.00-23.00-18.00-14.00-7.00
-400.00-233.33-350.00-460.00-450.00-900.00-600.00-440.00-262.50-190.00-190.91-210.00-191.67-112.50-60.87-20.59
-8.00-7.00-14.00-25.00-27.00-27.00-24.00-21.00-20.00-19.00-20.00-19.00-23.00-21.00-16.00-3.00
-33.33-12.50100.0078.578.00–-11.11-12.50-4.76-5.005.26-5.0021.05-8.70-23.81-81.25
0.190.200.280.340.390.400.400.601.201.681.802.022.022.022.022.02
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ImpediMed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ImpediMed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ImpediMed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ImpediMed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ImpediMed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ImpediMed stock margins

The ImpediMed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImpediMed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImpediMed.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
80.95 %
-252.46 %
-246.24 %
Jan 1, 2022
83.83 %
-187.84 %
-188.09 %
Jan 1, 2023
86.37 %
-187.39 %
-180.90 %
Jan 1, 2024
87.27 %
-205.67 %
-191.78 %
Jan 1, 2025
86.25 %
-180.82 %
-182.62 %
Jan 1, 2026 (e)
86.25 %
-112.90 %
-131.56 %
Jan 1, 2027 (e)
86.25 %
-62.27 %
-70.00 %
Jan 1, 2028 (e)
86.25 %
-22.80 %
-9.90 %

ImpediMed Stock Revenue, EBIT, Earnings per Share

The ImpediMed earnings per share therefore indicates how much revenue ImpediMed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.01 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2022
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2023
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2024
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2025
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2026 (e)
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2027 (e)
0.01 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2028 (e)
0.02 AUD
-0.00 AUD
-0.00 AUD

ImpediMed business model & stock analysis

ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion.

ImpediMed SWOT Analysis

Strengths

ImpediMed Ltd possesses a unique technology that enables the non-invasive assessment of physiological conditions through bioimpedance spectroscopy. This technology has allowed the development of innovative products that have the potential to revolutionize various medical fields.

ImpediMed Ltd holds a robust intellectual property portfolio, including patents and trademarks, which provide competitive advantages and barriers to entry for potential competitors. This strengthens the company's position in the market and enhances its ability to protect its innovative technology.

ImpediMed Ltd has successfully established a strong market presence by partnering with healthcare institutions and professionals worldwide. Its products have gained recognition for their accuracy and effectiveness, contributing to the company's reputation and brand value.

Weaknesses

ImpediMed Ltd heavily relies on strategic partnerships for distribution, marketing, and sales of its products. This dependency imposes a level of vulnerability on the company, as any disruptions or termination of partnerships could adversely impact its revenue and growth prospects.

While ImpediMed Ltd has made significant progress in expanding its market presence, there is still room for improvement in terms of market penetration. The company needs to further strengthen its marketing efforts and expand its customer base to drive greater adoption of its products.

Opportunities

The increasing preference for non-invasive medical technologies presents a significant opportunity for ImpediMed Ltd. With its unique bioimpedance spectroscopy technology, the company is well-positioned to meet the rising demand for accurate and non-invasive physiological assessments across various medical disciplines.

ImpediMed Ltd has the potential to expand its product offerings into new markets beyond its current focus areas. By identifying and targeting untapped markets, the company can diversify its revenue streams and reduce its dependence on specific regions or segments, thereby enhancing its growth prospects.

Threats

ImpediMed Ltd operates in a highly competitive industry, facing competition from both established medical device companies and emerging startups. The presence of numerous competitors increases the risk of pricing pressures and the need for continuous innovation to differentiate the company's products from others in the market.

The medical device industry is subject to strict regulatory requirements, which can pose challenges for product development, approvals, and commercialization. Additionally, reimbursement policies and limitations imposed by healthcare payers may impact the adoption and utilization of ImpediMed Ltd's products, potentially hindering market growth.

ImpediMed Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ImpediMed historical P/E ratio, EBIT multiple, and P/S ratio

ImpediMed annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ImpediMed shares outstanding

The number of shares of ImpediMed was 2.02 B in 2025. This indicates how many shares ImpediMed is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
1.20 B Stocks
Jan 1, 2022
1.68 B Stocks
Jan 1, 2023
1.80 B Stocks
Jan 1, 2024
2.02 B Stocks
Jan 1, 2025
2.02 B Stocks
Jan 1, 2026 (e)
2.02 B Stocks
Jan 1, 2027 (e)
2.02 B Stocks
Jan 1, 2028 (e)
2.02 B Stocks

Current ImpediMed forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
16.67 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
0.05
Last Price
0.01
Currency
AUD
12M Return Potential
750.00 %
LTM Return
0 %

ImpediMed Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/21/2024-0.01AUD-5.35 MAUD-2024 Q2
2/22/2023-0.01AUD-7.21 MAUD-2023 Q2
8/29/2022-0.01AUD-6.60 MAUD-2022 Q4
2/25/2022-0.01AUD-5.43 MAUD-2022 Q2
8/21/2019-0.03AUD-3.65 MAUD-2019 Q4

EESG©

Eulerpool ESG Scorecard© for the ImpediMed stock

29/100
5
Environment
55
Social
28
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees46.988
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ImpediMed shareholder structure

% Name
0.56699%
Eley Griffiths Group Pty. Ltd.
Eley Griffiths Group Pty. Ltd.
0.25817%
Emmanuel-Donnelly (Christine)
Emmanuel-Donnelly (Christine)
0.24284%
Delaney (Janelle)
Delaney (Janelle)
0.14725%
Grant (Andrew)
Grant (Andrew)
0.09773%
Bones (Fiona)
Bones (Fiona)
0.01493%
DFA Australia Ltd.
DFA Australia Ltd.

ImpediMed Executives and Management Board

13 members · 62 % women

DS

Mr. Dennis Schlaht

Senior Vice President - R&D and Technology

704,203.00 AUD

Management

MG

Mr. Mcgregor Grant

Chief Financial & Operating Officer, Executive Director · since 2023

584,094.00 AUD
PB

Dr. Parmjot Bains

Interim Chief Executive Officer, Managing Director, Executive Director · since 2024

433,696.00 AUD
TB

Mr. Tim Benkovic

Senior Vice President - Sales and Customer Success

–
SC

Mr. Steven Chen

Chief Medical Officer

–
LR

Ms. Leanne Ralph

Company Secretary

–
HH

Ms. Hannah Howlett

Investor Relations · since 2023

–

Board of Directors

CE

Ms. Christine Emmanuel-Donnelly

Non-Executive Independent Chairman of the Board

116,972.00 AUD
AG

Mr. Andrew Grant

Director · since 2023

86,087.00 AUD
JD

Ms. Janelle Delaney

Non-Executive Independent Director

83,983.00 AUD
FB

Ms. Fiona Bones

Non-Executive Independent Director

6,641.00 AUD
JK

Ms. Julie Kuhlken

Senior Director, Downstream Marketing

–
AM

Ms. Ashley Munoz

Director of Human Resources

–

Frequently asked questions about ImpediMed

The business model of ImpediMed Ltd focuses on developing and commercializing medical devices for measuring and monitoring fluid status and tissue impedance. ImpediMed specializes in bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) technologies, which are used in various medical fields such as lymphedema, heart failure, and chronic kidney disease. The company's products provide non-invasive measurements to help clinicians assess fluid status and tissue composition, aiding in the early detection and management of various medical conditions. ImpediMed's innovative devices and solutions contribute to improved patient outcomes and cost-effective healthcare interventions.

ImpediMed Ltd is primarily active in the healthcare industry.

The main competitors of ImpediMed Ltd in the market are [competitor names].

ImpediMed Ltd is an Australian-based medical technology company founded in 1999. The company specializes in the development and commercialization of bioimpedance spectroscopy (BIS) devices for non-invasive fluid management. ImpediMed's technology has applications in the areas of lymphedema management, early detection of secondary lymphedema, and monitoring of body composition in clinical and research settings. With a focus on improving patient outcomes, ImpediMed has established a strong reputation in the medical field. As a leading provider of BIS technology, ImpediMed continues to innovate and make advancements in the field of medical diagnostics and patient care.

ImpediMed Ltd, a leading medical technology company, has accomplished several significant milestones throughout its journey. The company successfully developed and commercialized its innovative bioimpedance spectroscopy technology, the L-Dex System. This revolutionary product enables early detection of lymphedema, a condition commonly associated with cancer treatment. ImpediMed also received FDA approval for its product, marking a crucial milestone in expanding its market reach. Furthermore, the company has made notable progress through strategic collaborations with prestigious medical institutions and key partnerships with renowned healthcare organizations. ImpediMed's commitment to advancing patient care, combined with its continuous technological advancements, showcases its substantial achievements in the medical technology industry.

ImpediMed Ltd is primarily present in several countries and regions worldwide. The company has a global presence with a focus on key markets including the United States, Australia, and Europe. ImpediMed operates in the healthcare industry, providing medical devices and solutions for the management and monitoring of lymphedema, heart failure, and body composition. With its innovative technologies and strong market penetration, ImpediMed continues to expand its presence and deliver its products to healthcare professionals and patients worldwide.

ImpediMed Ltd represents values of innovation, integrity, and dedication to improving healthcare outcomes. The company's corporate philosophy focuses on providing advanced and accurate medical devices and solutions for the assessment and monitoring of body composition and fluid status. ImpediMed is committed to delivering products that assist healthcare professionals in making informed decisions for better patient management. With a strong emphasis on research and development, ImpediMed continuously strives to revolutionize the field of bioimpedance spectroscopy, ensuring accurate and non-invasive measurements. By placing a significant emphasis on technological advancements, ImpediMed Ltd aims to transform patient care and improve overall health outcomes.

Analysts currently set an average price target of 0.05 AUD for the ImpediMed stock (median: 0.05 AUD), implying +707.5 % versus the latest price. The consensus is based on 8 analyst ratings.

ImpediMed Analyst Price Targets 2026

8 analysts currently rate the ImpediMed stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ImpediMed to generate revenue of 16.66 M AUD and earnings per share of -0.01 AUD.

ImpediMed Analyst Price Targets 2026

Converted at the current exchange rate, the ImpediMed share trades at 0.00 EUR (0.01 AUD).

The ImpediMed share (IPD.AX) is listed on 2 stock exchanges, including: ASX (IPD.AX).

ImpediMed Ltd is a global company specializing in the development of medical devices and solutions for measuring lymphedema and other fluid accumulation in the body. The company was founded in 1999 and is headquartered in Brisbane, Australia. ImpediMed is divided into two main business segments - ImpediMed and Sozo. ImpediMed specializes in the development of bioimpedance devices, while Sozo specializes in the measurement of body fluids by combining bioimpedance with other technologies such as optical imaging and sonography. Sozo specifically addresses data-driven clinical problems by providing doctors and nurses with an objective, automated method for measuring edema. ImpediMed's bioimpedance technology is mainly used for monitoring edema and other conditions caused by irregular fluid accumulation. The device measures the electrical resistance in the tissue, allowing for an accurate determination of extracellular fluid, intracellular fluid, and body fat percentage. ImpediMed's Sozo system combines bioimpedance with other technologies. It provides accurate measurement of extracellular fluid, which is essential for the diagnosis, monitoring, and therapy management of various diseases, including lymphedema. ImpediMed also offers training on specific diseases for doctors and nursing staff. ImpediMed specializes in developing medical products for the field of oncology and lymphedema patients. The company also offers specialized post-care for oncology patients by supporting monitoring for edema, swelling, and body fluids. ImpediMed has established itself as a leading provider of edema monitoring solutions and operates in Europe, Asia, North America, and Australia. The company is committed to providing its customers with reliable and accurate diagnoses to enable a good quality of life for people suffering from various edema conditions. It collaborates with specialized physicians in various medical fields. Overall, ImpediMed is a successful company that has found a niche in the medical industry with its bioimpedance technology. The variety of products and solutions it offers, along with collaborations with specialized physicians, have contributed to its establishment as a leading player in edema monitoring in a short period of time.

The expected revenue of ImpediMed is 16.66 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ImpediMed is -21.92 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ImpediMed is currently -0.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ImpediMed stock.

The price-to-sales ratio (P/S) of ImpediMed is currently 0.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ImpediMed stock.

The Eulerpool Quality Score for ImpediMed is 4/10.

The ISIN of ImpediMed is AU000000IPD8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ImpediMed is IPD.AX. The ticker symbol is used to trade ImpediMed shares on the stock exchange.

ImpediMed paid dividends every year for the past 0 years.

ImpediMed is assigned to the 'Health' sector.

The dividends of ImpediMed are distributed in AUD.

All fundamentals and in-depth analysis of ImpediMed

Our stock analysis for ImpediMed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ImpediMed Stock
ImpediMed Revenue→
ImpediMed Stock
ImpediMed Net Income→
ImpediMed Stock
ImpediMed P/E→
ImpediMed Stock
ImpediMed P/S→
ImpediMed Stock
ImpediMed EBIT→
ImpediMed Stock
ImpediMed Dividend→
ImpediMed Stock
ImpediMed Directors Dealings→
ImpediMed Stock
ImpediMed Stocks→
ImpediMed Stock
ImpediMed Market capitalization→
ImpediMed Stock
ImpediMed Debt→
ImpediMed Stock
ImpediMed Liabilities→
ImpediMed Stock
ImpediMed Equity→
ImpediMed Stock
ImpediMed AAQS→
ImpediMed Stock
ImpediMed Employees→
ImpediMed Stock
ImpediMed ROE→
ImpediMed Stock
ImpediMed ROA→
ImpediMed Stock
ImpediMed ROCE→
ImpediMed Stock
ImpediMed News→
ImpediMed Stock
ImpediMed Analyst Price Targets→

Health Stocks

ImplanetImmutep Ltd ADRImprove Medical Instruments CoImmutepImugeneImmuron Ltd ADRImunonImmuronIMVImmuPharmaIN8bioImmunovia AB (publ)All Stocks A–Z →